Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Gina Fusaro_2023
VIEWPOINTS

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Shots:Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanomaShe also spoke on the epidemiology of melanoma and…
May 16, 2023

Read more

VIEWPOINTS_Daniel Quirk_2023
VIEWPOINTS

Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots:Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque PsoriasisHe also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023

Read more

Load more